These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25711511)

  • 1. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
    Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
    Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
    Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
    Yamamoto N; Murakami H; Nishina T; Hirashima T; Sugio K; Muro K; Takahashi T; Naito T; Yasui H; Akinaga S; Koh Y; Boku N
    Ann Oncol; 2013 Jun; 24(6):1653-9. PubMed ID: 23413279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
    Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
    Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
    Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
    Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
    Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
    Santoro A; Simonelli M; Rodriguez-Lope C; Zucali P; Camacho LH; Granito A; Senzer N; Rimassa L; Abbadessa G; Schwartz B; Lamar M; Savage RE; Bruix J
    Br J Cancer; 2013 Jan; 108(1):21-4. PubMed ID: 23287988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
    Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
    Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
    Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
    Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
    Liu SV; Groshen SG; Kelly K; Reckamp KL; Belani C; Synold TW; Goldkorn A; Gitlitz BJ; Cristea MC; Gong IY; Semrad TJ; Xu Y; Xu T; Koczywas M; Gandara DR; Newman EM
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):723-732. PubMed ID: 30128950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
    Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.